Home | Business News | Browse by Publication | P | PR Newswire

Halozyme Therapeutics Reports Fourth Quarter and Year End 2005 Financial Results.

Article Excerpt
- Conference Call and Webcast Today at 8:00 a.m. PDT -

SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today reported financial results for the three months and year ended December 31, 2005.

"We continue to make solid progress on all fronts and are meeting our milestones, including the recent completion of our INFUSE-LR study and the completion of patient enrollment in our Chemophase(R) Phase I clinical trial," stated Jonathan Lim, MD, Halozyme's President and CEO. "We are extremely pleased with the continued advancement of our lead oncology product candidate, Chemophase, and we are excited about commercializing our Hylenex product."

Fourth Quarter 2005 and Subsequent Weeks' Highlights * The completion of patient enrollment for the Chemophase Phase I clinical trial. The initial clinical protocol for Chemophase was designed to evaluate a single intravesical (into the bladder) administration of Chemophase along with the widely used anticancer drug mitomycin in patients with superficial bladder cancer. The Phase I study completed its target enrollment of five patients with superficial bladder cancer. The objectives of the study were to determine the safety, tolerability and pharmacokinetics of Chemophase administered intravesically with mitomycin. The study was conducted at BCG Oncology in Phoenix, Arizona under the supervision of Donald L. Lamm, MD, the principal investigator. * The completion of the INFUSE-LR clinical trial, a clinical trial of subcutaneous (Sub-Q) infusion (hypodermoclysis) with Hylenex. The use of Hylenex preceding Sub-Q infusion of...